External quality assessment scheme 2011 for Neisseria meningitidis
This report on EQA performance shows that European Reference Laboratories for Meningococci differ in their capacities and the level of characterisation of the distributed N. meningitidis material, but that there have been improvements since the first ECDC IBD-labnet distribution.
Surveillance network for Invasive Neisseria Meningitidis in Europe 1999 - 2000
Surveillance network for Invasive Neisseria Meningitidis in Europe 2001
Surveillance network for Invasive Neisseria Meningitidis in Europe 2002
Surveillance network for Invasive Neisseria Meningitidis in Europe 2003/2004
EU-IBIS, a surveillance network for invasive meningococcal disease, continues to fulfil its aims to gather and improve epidemiological information about the disease, to integrate and analyse molecular data, and to form the focus for a wider collaboration.
Surveillance of invasive bacterial diseases in Europe, 2012
This report describes the occurrence of invasive bacterial diseases (IBD) in Europe during 2012, based on data collected through The European Surveillance System (TESSy).
Impact on disease incidence of a routine universal and catch-up vaccination strategy against Neisseria meningitidis C in Tuscany, ItalyArchived
Findings in this study confirmed the herd immunity effect of immunizing young children, since invasive meningococcal disease was not only reduced among vaccinees, but in all age groups.
ECDC Vaccine Scheduler
The Vaccine Scheduler is an interactive tool that shows vaccination schedules for individual EU/EEA countries and specific age groups. With this tool comparisons can be made for vaccination schedules between two countries or by disease for all or a selection of countries.
- Hepatitis A
- Hepatitis B
- Human papillomavirus infection
- Influenza in humans, seasonal
- Invasive Haemophilus influenzae disease
- Meningococcal disease
- Pneumococcal disease
- Prevention and control
- Rotavirus infection
- Tick-borne diseases
Expert opinion on the introduction of the meningococcal B (4CMenB) vaccine in the EU/EEA
This expert opinion is intended to support national decision-making by summarising the considerations and concerns of some EU/EEA countries when they discussed whether to introduce the 4CMenB vaccine into their national immunisation programmes.